1606 Corp. signs LOI for strategic stake in AI drug-discovery firm Adnexus Biotechnologies

1606 CORP.

Signed LOI to acquire a strategic stake in Adnexus Biotechnologies; no deal value disclosed.
Adnexus operates SUTRA AI platform for infectious/neurological disease drug discovery.
SUTRA platform includes data on 19 viruses, 8M molecules, and human microbiome samples.
Transaction subject to due diligence and standard conditions; no expected close date given.
Both CEOs expressed optimism about the partnership advancing AI-driven drug development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.